In-situ polymerization-mediated glycan density measurement on extracellular vesicle surface for acute myeloid leukemia diagnosis
A new blood test using microfluidic technology could help doctors diagnose acute myeloid leukemia more quickly and reliably by measuring specific markers on cancer-derived particles.
A novel microfluidic biosensor normalizes extracellular vesicle glycan density to reduce inter-patient variability, achieving AUC=0.904 in 47 clinical specimens for AML diagnosis. The wash-free, rapid platform represents a clinically translatable blood-based diagnostic approach for acute myeloid leukemia.
What the study was
- Study design
- Validation study (prospective clinical specimens, 47 patients)
- Population
- 16 AML patients, 15 benign hematological disease patients, 16 healthy donors
- Sample size
- 47
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Journal of Nanobiotechnology
Why it surfaced
Novel EV-based AML diagnostic platform achieves AUC=0.904 in clinical specimens; glycan density normalization addresses key translational barrier (inter-patient variability); blood-based, rapid workflow with point-of-care potential. Capped design_quality=1 due to small validation set (n=47, single center).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.